



12 September 2019

AIM: RENE

ReNeuron Group plc
("ReNeuron" or the "Company")

Result of AGM

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that all resolutions put to shareholders at its Annual General Meeting ("AGM") held earlier today were duly passed.

ENDS

ENQUIRIES:

ReNeuron +44 (0)20 3819 8400
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer

Buchanan (UK) +44 (0) 20 7466 5000
Mark Court, Sophie Wills, Tilly Abraham

Argot Partners (US) +1 212 600 1902
Stephanie Marks, Claudia Styslinger

Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison
(NOMAD and Joint Broker)

N+1 Singer +44 (0) 20 7496 3000
Aubrey Powell, James Moat, Mia Gardner
(Joint Broker)

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.